Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis
Condition: DKA Intervention: Drug: Insulin Glargine Sponsor: HealthPartners Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
Conditions: Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients; Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect; 128 Patients Were Randomly Assigned 1:1; Metformin and Insulin Glargine Combin ed With Chiglitazar Sodium Tablets 48mg/ Day Group; Metformin and Insulin Glargine Combined With Placebo Group; InvestigatorInitiate Trial; Changes in HbA1C From Baseline at 18 Weeks of Treatment Interventions: Drug: Chiglitazar sodium; Drug: Chiglitazar placebo Sponsor: Yanbing Li Not yet rec...
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis
Condition: DKA Intervention: Drug: Insulin Glargine Sponsor: HealthPartners Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
Conditions: Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients; Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect; 128 Patients Were Randomly Assigned 1:1; Metformin and Insulin Glargine Combin ed With Chiglitazar Sodium Tablets 48mg/ Day Group; Metformin and Insulin Glargine Combined With Placebo Group; InvestigatorInitiate Trial; Changes in HbA1C From Baseline at 18 Weeks of Treatment Interventions: Drug: Chiglitazar sodium; Drug: Chiglitazar placebo Sponsor: Yanbing Li Not yet rec...
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis
Condition: DKA Intervention: Drug: Insulin Glargine Sponsor: HealthPartners Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
Conditions: Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients; Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect; 128 Patients Were Randomly Assigned 1:1; Metformin and Insulin Glargine Combin ed With Chiglitazar Sodium Tablets 48mg/ Day Group; Metformin and Insulin Glargine Combined With Placebo Group; InvestigatorInitiate Trial; Changes in HbA1C From Baseline at 18 Weeks of Treatment Interventions: Drug: Chiglitazar sodium; Drug: Chiglitazar placebo Sponsor: Yanbing Li Not yet rec...
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis
Condition: DKA Intervention: Drug: Insulin Glargine Sponsor: HealthPartners Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
Conditions: Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients; Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect; 128 Patients Were Randomly Assigned 1:1; Metformin and Insulin Glargine Combin ed With Chiglitazar Sodium Tablets 48mg/ Day Group; Metformin and Insulin Glargine Combined With Placebo Group; InvestigatorInitiate Trial; Changes in HbA1C From Baseline at 18 Weeks of Treatment Interventions: Drug: Chiglitazar sodium; Drug: Chiglitazar placebo Sponsor: Yanbing Li Not yet rec...
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis
Condition: DKA Intervention: Drug: Insulin Glargine Sponsor: HealthPartners Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
Conditions: Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients; Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect; 128 Patients Were Randomly Assigned 1:1; Metformin and Insulin Glargine Combin ed With Chiglitazar Sodium Tablets 48mg/ Day Group; Metformin and Insulin Glargine Combined With Placebo Group; InvestigatorInitiate Trial; Changes in HbA1C From Baseline at 18 Weeks of Treatment Interventions: Drug: Chiglitazar sodium; Drug: Chiglitazar placebo Sponsor: Yanbing Li Not yet rec...
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Conditions: Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease Interventions: Drug: Orforglipron; Drug: Insulin Glargine Sponsor: Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 7, 2023 Category: Research Source Type: clinical trials
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Conditions: Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease Interventions: Drug: Orforglipron; Drug: Insulin Glargine Sponsor: Eli Lilly and Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 7, 2023 Category: Research Source Type: clinical trials
